News & Updates
Filter by Specialty:

NIAGARA interim data support perioperative durvalumab for MIBC
In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).
NIAGARA interim data support perioperative durvalumab for MIBC
10 Oct 2024
KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).
KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
09 Oct 2024
Intravenous PCA with hydromorphone outperforms oral morphine for severe cancer pain
In the management of severe cancer pain, intravenous patient-controlled analgesia (PCA) with hydromorphone delivers superior pain control with greater patient satisfaction as compared with conventional oral morphine, according to the phase III open-label SYLT-021 study.
Intravenous PCA with hydromorphone outperforms oral morphine for severe cancer pain
08 Oct 2024
Cemiplimab improves 5-year survival in advanced NSCLC
First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.
Cemiplimab improves 5-year survival in advanced NSCLC
08 Oct 2024
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
07 Oct 2024
New model predicts HCC risk in noncirrhotic CHB patients
A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.